




RealRate

PHARMACEUTICAL 2018

Imunon Inc.
Rank 186 of 342





PHARMACEUTICAL 2018

Imunon Inc.
Rank 186 of 342



The relative strengths and weaknesses of Imunon Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Imunon Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 88% points. The greatest weakness of Imunon Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 73% points.

The company's Economic Capital Ratio, given in the ranking table, is 75%, being 29% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	24,312
Cost of Goods Sold	0
Intangible Assets	2,772
Liabilities, Current	6,200
Liabilities, Non-Current	72
Other Assets	20,255
Other Compr. Net Income	-10
Other Expenses	0
Other Liabilities	14,539
Other Net Income	-1,434
Other Revenues	0
Property and Equipment	176
Research and Development	13,079
Selling, General and Administrative Expense	5,890

Output Variable	Value in 1000 USD
Assets	47,514
Liabilities	20,810
Expenses	18,968
Revenues	0
Stockholders Equity	26,705
Net Income	-20,402
Comprehensive Net Income	-20,407
Economic Capital Ratio	75%